Financial Life Planners’s Recursion Pharmaceuticals RXRX Stock Holding History

Financial Life Planners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11K	Hold	2,986	–	–	0.01%	231
2026 Q1	$9.17K	Buy	+2,986	New	+$11.5K	0.01%	242
2025 Q4	–	Sell	-2,986	Closed	-$14.6K	–	272
2025 Q3	$14.6K	Buy	+2,986	New	+$15.7K	0.01%	224
2025 Q1	–	Sell	-2,986	Closed	-$20.2K	–	312
2024 Q4	$20.2K	Buy	+2,986	New	+$20.1K	0.02%	206

Other funds holding RXRX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $246M AUM 51.29% 1-Year Est. Return

TMC

Themes Management Co Greenwich, Connecticut $151M AUM

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return

NWMG

National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return

WPC

Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return

Financial Life Planners's RXRX Position: Q2 2026 in Review

Financial Life Planners held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 2,986 shares worth $11K. The position accounts for 0.01% of the portfolio, ranked #231.

Financial Life Planners first reported a position in RXRX in Q4 2024 and has held it in 4 quarters since. The position peaked at $20.2K in Q4 2024. 35 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Financial Life Planners held 2,986 shares of Recursion Pharmaceuticals worth $11K as of Q2 2026.
Financial Life Planners left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up 0.01% of Financial Life Planners's portfolio in Q2 2026, its #231 holding.
Financial Life Planners first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
Financial Life Planners's Recursion Pharmaceuticals position peaked at $20.2K in Q4 2024.
35 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Financial Life Planners's 13F filing for Q2 2026, filed 21 Jul 2026.